Bristol Myers Squibb NDA for Mezigdomide Accepted by FDA
PRINCETON, New Jersey, July 13, 2026 Bristol Myers Squibb (BMS) has announced that the U.S. Food and Drug Administration...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PRINCETON, New Jersey, July 13, 2026 Bristol Myers Squibb (BMS) has announced that the U.S. Food and Drug Administration...
SANTA CLARA, California, USA, July 8, 2026 Agilent Technologies has expanded its Altura High-Performance Liquid Chromatography (HPLC) portfolio with...
BOSTON, Massachusetts, USA, July 9, 2026 Mindbeam Research has unveiled a significant advance in AI-driven drug discovery, demonstrating how...
HONG KONG, China, July 12, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), and...
